Arrowhead Pharmaceuticals Stock Alpha and Beta Analysis
| ARWR Stock | USD 65.49 0.49 0.75% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Arrowhead Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Arrowhead Pharmaceuticals over a specified time horizon. Remember, high Arrowhead Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Arrowhead Pharmaceuticals' market risk premium analysis include:
Beta 2.2 | Alpha 0.79 | Risk 5.26 | Sharpe Ratio 0.21 | Expected Return 1.09 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Arrowhead | Build AI portfolio with Arrowhead Stock |
Arrowhead Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Arrowhead Pharmaceuticals market risk premium is the additional return an investor will receive from holding Arrowhead Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Arrowhead Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Arrowhead Pharmaceuticals' performance over market.| α | 0.79 | β | 2.20 |
Arrowhead Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Arrowhead Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Arrowhead Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Arrowhead Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Arrowhead Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Arrowhead Pharmaceuticals shares will generate the highest return on investment. By understating and applying Arrowhead Pharmaceuticals stock market price indicators, traders can identify Arrowhead Pharmaceuticals position entry and exit signals to maximize returns.
Arrowhead Pharmaceuticals Return and Market Media
The median price of Arrowhead Pharmaceuticals for the period between Sat, Oct 11, 2025 and Fri, Jan 9, 2026 is 42.31 with a coefficient of variation of 27.03. The daily time series for the period is distributed with a sample standard deviation of 13.78, arithmetic mean of 50.97, and mean deviation of 13.12. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Arrowhead Q4 2025 Earnings Call Transcript | 11/25/2025 |
2 | 11,795 Shares in Arrowhead Pharmaceuticals, Inc. ARWR Acquired by Scotia Capital Inc. | 12/04/2025 |
3 | Acquisition by Christopher Anzalone of 180000 shares of Arrowhead Pharmaceuticals subject to Rule 16b-3 | 12/12/2025 |
4 | Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635 | 12/15/2025 |
5 | Disposition of 3221 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 67.87 subject to Rule 16b-3 | 12/16/2025 |
6 | Arrowhead Pharmaceuticals Is Down 6.1 percent After First CNS RNAi Alzheimers Trial Dosing Has The Bull Case Changed | 12/19/2025 |
7 | Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events | 12/23/2025 |
8 | Disposition of 7530 shares by Ferrari Mauro of Arrowhead Pharmaceuticals at 70.0 subject to Rule 16b-3 | 12/26/2025 |
9 | Disposition of 16545 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 6.15 subject to Rule 16b-3 | 12/29/2025 |
10 | Insider Selling Arrowhead Pharmaceuticals Director Sells 7,530 Shares of Stock | 12/31/2025 |
11 | Disposition of 5771 shares by Christopher Anzalone of Arrowhead Pharmaceuticals at 66. subject to Rule 16b-3 | 01/02/2026 |
12 | Disposition of 309 shares by Hamilton James C of Arrowhead Pharmaceuticals at 68.0 subject to Rule 16b-3 | 01/05/2026 |
13 | Disposition of 440 shares by Obrien Patrick of Arrowhead Pharmaceuticals subject to Rule 16b-3 | 01/06/2026 |
14 | Assessing Arrowhead Pharmaceuticals Valuation After Obesity Trial Progress And New REDEMPLO Approvals | 01/08/2026 |
About Arrowhead Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Arrowhead or other stocks. Alpha measures the amount that position in Arrowhead Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2011 | 2025 | 2026 (projected) | Payables Turnover | 0.0261 | 0.54 | 0.48 | 0.51 | Days Of Inventory On Hand | 214.36 | 54.6K | 49.1K | 51.6K |
Arrowhead Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Arrowhead Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Arrowhead Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Arrowhead Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Arrowhead Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Arrowhead Pharmaceuticals' management manipulating its earnings.
| 6th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of December 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of September 2023 Last Financial Announcement | View |
Build Portfolio with Arrowhead Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Arrowhead Stock Analysis
When running Arrowhead Pharmaceuticals' price analysis, check to measure Arrowhead Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arrowhead Pharmaceuticals is operating at the current time. Most of Arrowhead Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Arrowhead Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arrowhead Pharmaceuticals' price. Additionally, you may evaluate how the addition of Arrowhead Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.